These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 24786587)
1. In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis. Chamakh-Ayari R; Bras-Gonçalves R; Bahi-Jaber N; Petitdidier E; Markikou-Ouni W; Aoun K; Moreno J; Carrillo E; Salotra P; Kaushal H; Negi NS; Arevalo J; Falconi-Agapito F; Privat A; Cruz M; Pagniez J; Papierok GM; Rhouma FB; Torres P; Lemesre JL; Chenik M; Meddeb-Garnaoui A PLoS One; 2014; 9(5):e92708. PubMed ID: 24786587 [TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum. Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507 [TBL] [Abstract][Full Text] [Related]
8. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086 [TBL] [Abstract][Full Text] [Related]
9. The F1F3 Recombinant Chimera of Alves-Silva MV; Nico D; de Luca PM; Palatnik de-Sousa CB Front Immunol; 2019; 10():724. PubMed ID: 31024556 [No Abstract] [Full Text] [Related]
10. F1 Domain of the Carrillo E; Fernandez L; Ibarra-Meneses AV; Santos MLB; Nico D; de Luca PM; Correa CB; de Almeida RP; Moreno J; Palatnik-de-Sousa CB Front Immunol; 2017; 8():750. PubMed ID: 28747911 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455 [TBL] [Abstract][Full Text] [Related]
12. Phenotypic and Functional Profiles of Antigen-Specific CD4 Egui A; Ledesma D; Pérez-Antón E; Montoya A; Gómez I; Robledo SM; Infante JJ; Vélez ID; López MC; Thomas MC Front Cell Infect Microbiol; 2018; 8():393. PubMed ID: 30510917 [TBL] [Abstract][Full Text] [Related]
13. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Handman E; Symons FM; Baldwin TM; Curtis JM; Scheerlinck JP Infect Immun; 1995 Nov; 63(11):4261-7. PubMed ID: 7591056 [TBL] [Abstract][Full Text] [Related]
14. Leishmanial amastigote antigen P-2 induces major histocompatibility complex class II-dependent natural killer-cell reactivity in cells from healthy donors. Nylén S; Maasho K; McMahon-Pratt D; Akuffo H Scand J Immunol; 2004 Mar; 59(3):294-304. PubMed ID: 15030581 [TBL] [Abstract][Full Text] [Related]
15. Leishmania infantum transfected with toxic plasmid induces protection in mice infected with wild type L. infantum or L. amazonensis. Zorgi NE; Arruda LV; Paladine I; Roque GAS; Araújo TF; Brocchi M; Barral M; Sanchiz Á; Requena JM; Abánades DR; Giorgio S Mol Immunol; 2020 Nov; 127():95-106. PubMed ID: 32949849 [TBL] [Abstract][Full Text] [Related]
16. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant. Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354 [TBL] [Abstract][Full Text] [Related]
17. Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis. Carvalho AM; Magalhães A; Carvalho LP; Bacellar O; Scott P; Carvalho EM BMC Infect Dis; 2013 Nov; 13():529. PubMed ID: 24206576 [TBL] [Abstract][Full Text] [Related]
18. Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis. de Mendonça LZ; Resende LA; Lanna MF; Aguiar-Soares RD; Roatt BM; Castro RA; Batista MA; Silveira-Lemos D; Gomes Jde A; Fujiwara RT; Rezende SA; Martins-Filho OA; Corrêa-Oliveira R; Dutra WO; Reis AB; Giunchetti RC Parasit Vectors; 2016 Aug; 9(1):472. PubMed ID: 27577735 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice. Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908 [TBL] [Abstract][Full Text] [Related]
20. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. Stäger S; Smith DF; Kaye PM J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]